News Sanofi $750m acquisition gives it edge in flu vacccine marke... Biotech's Flublok is only FDA-approved cell-based flu jab
R&D Harnessing the cell's own degradation machinery, with Benedi... Benedict Cross, Chief Technology Officer at PhoreMost, discusses targeted protein degradation.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
